Usana Health Sciences (USNA) Price to Sales (2010 - 2026)

Usana Health Sciences (USNA) has reported Price to Sales for 17 consecutive years, with 1.78 the latest figure, recorded in Q3 2026.

• On a quarterly basis, Price to Sales fell 26.21% year-over-year to 1.78 in Q3 2026; TTM through Jul 2026 was 0.43, a 31.22% decrease from a year earlier, with the FY2026 full-year figure at 0.38, down 51.76% from the prior year.
• Price to Sales was 1.78 for Q3 2026 at Usana Health Sciences, up from 1.25 in the prior quarter.
• Over five years, Price to Sales peaked at 5.58 in Q2 2022 and troughed at 1.25 in Q2 2026.
• A 5-year average of 3.78 and a median of 4.06 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales advanced 13.88% in 2023 and sank 50.67% in 2026, its largest moves.
• Over 5 years, Price to Sales stood at 4.48 in 2022, then increased by 3.47% to 4.64 in 2023, then tumbled by 31.32% to 3.19 in 2024, then slipped by 23.4% to 2.44 in 2025, then retreated by 27.09% to 1.78 in 2026.
• The last three Price to Sales figures came in at 1.78 (Q3 2026), 1.25 (Q2 2026), and 1.57 (Q1 2026), per Business Quant data.